In a single-site study, it reduced Insomnia Severity Index scores by an average of 65%, with all participants seeing symptom improvement.

There is a dramatic change in FDA adverse event reporting for mandibular advancement devices for obstructive sleep apnea in 2024 and 2025. Is it better reporting, a safety flag, or something else?

The new funding opportunity aims to develop closed-loop technologies that objectively measure and adaptively correct poor sleep at home.

Sleep Review's CPAP adherence solutions guide compares options on parameters including supporting evidence, patient and provider contact frequency, pricing structure, and more.

The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. FDA approves Orzeyful for narcolepsy The FDA approve...

The CND Life Sciences funding will support the commercial expansion and innovation of a skin biopsy-based test used in evaluating REM sleep behavior disorder and other synucleinopathies.

Significant changes to unattended sleep testing coding are on the horizon, making now the perfect time for practices to prepare. At Business of Sleep Medicine, attendees can join the session “Updates in Sleep Medicine Bi...

A newly developed foundation model analyzes standard polysomnogram data to identify patient groups with varying long-term health risks.

A new Swiss study reveals how the brain reorganizes sensory processing as it shifts into REM sleep, turning its listening inward to preserve cardiac signals.

On Aug. 5, 2026, Takeda announced that the U.S. Food and Drug Administration approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. Orzeyful is the first medicine approved to treat narc...